Perioperative Pembrolizumab Benefits Persist at 5-Year NSCLC Update

The use of pembrolizumab (Keytruda) before and after surgery reduced the risk of death by 26% compared with placebo for patients with early-stage non–small cell lung cancer (NSCLC), according to a 5-year follow-up of the KEYNOTE-671 study…